NATCO PHARMA
Back to Income Statement
|
NATCO PHARMA Last 5 Year Consolidated Net Profit History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Consolidated Net Profit | ₹1,885 Cr | ₹1,388 Cr | ₹715 Cr | ₹170 Cr | ₹441 Cr |
What is the latest Consolidated Net Profit of NATCO PHARMA ?
| Year | Consolidated Net Profit |
|---|---|
| Mar2025 | ₹1,885 Cr |
| Mar2024 | ₹1,388 Cr |
| Mar2023 | ₹715 Cr |
| Mar2022 | ₹170 Cr |
| Mar2021 | ₹441 Cr |
How is Consolidated Net Profit of NATCO PHARMA Trending?
| Years | Consolidated Net Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹1,885 Cr | 35.81 | |
| Mar2024 | ₹1,388 Cr | 94.09 | |
| Mar2023 | ₹715 Cr | 320.76 | |
| Mar2022 | ₹170 Cr | -61.44 | |
| Mar2021 | ₹441 Cr | - | |
Compare Consolidated Net Profit of peers of NATCO PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATCO PHARMA | ₹17,131.8 Cr | -4.6% | 12.4% | 23.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹432,000.0 Cr | -0.4% | 5.3% | 13.4% | Stock Analytics | |
| DIVIS LABORATORIES | ₹161,076.0 Cr | -4.3% | -6.3% | 12.3% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹148,510.0 Cr | 0.4% | 8.2% | 44.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹107,921.0 Cr | 0.5% | 1.8% | 16.4% | Stock Analytics | |
| CIPLA | ₹106,150.0 Cr | -0.8% | -2.6% | -9.2% | Stock Analytics | |
NATCO PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATCO PHARMA | -4.6% |
12.4% |
23.2% |
| SENSEX | -5.5% |
-11.5% |
0.3% |
You may also like the below Video Courses